Cart
sales@molnova.com
NNGH
CAS No. 161314-17-6
NNGH( —— )
Catalog No. M33755 CAS No. 161314-17-6
NNGH is a matrix metalloproteinase 3 (MMP-3) inhibitor with anticancer activity that counteracts the inhibitory effects of E2 and DHT on RANKL membrane binding.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 160 | In Stock |
|
| 10MG | 236 | In Stock |
|
| 25MG | 398 | In Stock |
|
| 50MG | 569 | In Stock |
|
| 100MG | 806 | In Stock |
|
| 200MG | 1079 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNNGH
-
NoteResearch use only, not for human use.
-
Brief DescriptionNNGH is a matrix metalloproteinase 3 (MMP-3) inhibitor with anticancer activity that counteracts the inhibitory effects of E2 and DHT on RANKL membrane binding.
-
DescriptionNNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetMMP
-
RecptorMMP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number161314-17-6
-
Formula Weight316.37
-
Molecular FormulaC13H20N2O5S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NO)CN(CC(C)C)S(=O)(=O)C1=CC=C(OC)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Laurence Blavier, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 2010 Jul 15;10(2):198-208.?
molnova catalog
related products
-
JC-10
JC-10 is a potent inhibitor of metalloproteinases and is often used as a probe.
-
Ramelteon
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).
-
Aderamastat
Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor used for research in allergic asthma, COPD, and pulmonary fibrosis.
